Intrahepatic Cholangiocarcinoma: New Insights in Pathology

 

 Buy Article Permissions and Reprints

ABSTRACT

Cholangiocarcinomas are malignant tumors that derive from cholangiocytes of small intrahepatic bile ducts or bile ductules (intrahepatic cholangiocarcinoma; ICC), or of large hilar or extrahepatic bile ducts (extrahepatic cholangiocarcinoma; ECC). ICC and ECC differ in morphology, pathogenesis, risk factors, treatment, and prognosis. This review focuses on ICC, which is rising in incidence with the emergence of hepatitis C virus (HCV) infection as a risk factor. The authors examined 73 ICC, which were resected at The Mount Sinai Medical Center in New York City, and reviewed the literature. The tumors were categorized into classical and nonclassical ICCs based on histopathology. Classical ICCs (54.8%) were characterized by a tubular, glandular, or nested pattern of growth, were significantly associated with tumor size of more than 5 cm and the absence of underlying liver disease and/or advanced fibrosis. Nonclassical ICCs (45.2%) consisted of tumors with trabecular architecture, tumors that exhibited features of extrahepatic carcinomas, and carcinomas considered to be derived from hepatic progenitor cells, i.e., combined hepatocellular/cholangiocarcinomas and cholangiolocellular carcinomas (ductular type of ICC). They were smaller and often arose in chronic liver disease, mostly HCV infection, and/or with significant fibrosis. The role of immunohistochemistry in the diagnosis of ICC and the importance of the new American Joint Committee on Cancer Staging System for ICC are also discussed.

REFERENCES

• 1 Nakanuma Y, Curado M P, Franceschi S et al.. Intrahepatic cholangiocarcinoma. In: Bosman F T, Carneiro F, Hruban R H, Theise N D, eds. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010: 217-224
  Google Scholar
• 2 Anthony P P. Tumours and tumour-like lesions of the liver and the biliary tract: aetiology, epidemiology and pathology. In: MacSween R NM, Burt A D, Portmann B C, Ishak K G, Scheuer P J, Anthony P P, eds. Pathology of the Liver. London: Churchill Livingstone; 2002: 711-775
  Google Scholar
• 3 Malhi H, Gores G J. Cholangiocarcinoma: modern advances in understanding a deadly old disease.  J Hepatol. 2006;  45 (6) 856-867
  CrossrefPubMedGoogle Scholar
• 4 Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology.  J Gastroenterol Hepatol. 2002;  17 (10) 1049-1055
  CrossrefPubMedGoogle Scholar
• 5 Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the port hepatis: an unusual tumor with distinctive clinical and pathological features.  Am J Med. 1965;  38 241-256
  CrossrefPubMedGoogle Scholar
• 6 Okuda K, Kubo Y, Okazaki N, Arishima T, Hashimoto M. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases.  Cancer. 1977;  39 (1) 232-246
  CrossrefPubMedGoogle Scholar
• 7 Aishima S, Kuroda Y, Nishihara Y et al.. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.  Am J Surg Pathol. 2007;  31 (7) 1059-1067
  CrossrefPubMedGoogle Scholar
• 8 Khan S A, Thomas H C, Davidson B R, Taylor-Robinson S D. Cholangiocarcinoma.  Lancet. 2005;  366 (9493) 1303-1314
  CrossrefPubMedGoogle Scholar
• 9 Konstadoulakis M M, Roayaie S, Gomatos I P et al.. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome.  Surgery. 2008;  143 (3) 366-374
  CrossrefPubMedGoogle Scholar
• 10 Endo I, Gonen M, Yopp A C et al.. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.  Ann Surg. 2008;  248 (1) 84-96
  CrossrefPubMedGoogle Scholar
• 11 Blechacz B, Gores G J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.  Hepatology. 2008;  48 (1) 308-321
  CrossrefPubMedGoogle Scholar
• 12 Nathan H, Pawlik T M, Wolfgang C L, Choti M A, Cameron J L, Schulick R D. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis.  J Gastrointest Surg. 2007;  11 (11) 1488-1496, discussion 1496–1497
  CrossrefPubMedGoogle Scholar
• 13 Khan S A, Toledano M B, Taylor-Robinson S D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.  HPB (Oxford). 2008;  10 (2) 77-82
  CrossrefPubMedGoogle Scholar
• 14 Shaib Y, El-Serag H B. The epidemiology of cholangiocarcinoma.  Semin Liver Dis. 2004;  24 (2) 115-125
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Hammill C W, Wong L L. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance.  J Am Coll Surg. 2008;  207 (4) 594-603
  CrossrefPubMedGoogle Scholar
• 16 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.  Hepatology. 2001;  33 (6) 1353-1357
  CrossrefPubMedGoogle Scholar
• 17 Shaib Y H, Davila J A, McGlynn K, El-Serag H B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?.  J Hepatol. 2004;  40 (3) 472-477
  CrossrefPubMedGoogle Scholar
• 18 Gatto M, Bragazzi M C, Semeraro R et al.. Cholangiocarcinoma: update and future perspectives.  Dig Liver Dis. 2010;  42 (4) 253-260
  CrossrefPubMedGoogle Scholar
• 19 Welzel T M, McGlynn K A, Hsing A W, O'Brien T R, Pfeiffer R M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.  J Natl Cancer Inst. 2006;  98 (12) 873-875
  CrossrefPubMedGoogle Scholar
• 20 West J, Wood H, Logan R F, Quinn M, Aithal G P. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.  Br J Cancer. 2006;  94 (11) 1751-1758
  CrossrefPubMedGoogle Scholar
• 21 Donato F, Gelatti U, Tagger A et al.. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.  Cancer Causes Control. 2001;  12 (10) 959-964
  CrossrefPubMedGoogle Scholar
• 22 Yamamoto S, Kubo S, Hai S et al.. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.  Cancer Sci. 2004;  95 (7) 592-595
  CrossrefPubMedGoogle Scholar
• 23 Tomimatsu M, Ishiguro N, Taniai M et al.. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.  Cancer. 1993;  72 (3) 683-688
  CrossrefPubMedGoogle Scholar
• 24 Kobayashi M, Ikeda K, Saitoh S et al.. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis.  Cancer. 2000;  88 (11) 2471-2477
  CrossrefPubMedGoogle Scholar
• 25 Shaib Y H, El-Serag H B, Nooka A K et al.. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.  Am J Gastroenterol. 2007;  102 (5) 1016-1021
  CrossrefPubMedGoogle Scholar
• 26 El-Serag H B, Engels E A, Landgren O et al.. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.  Hepatology. 2009;  49 (1) 116-123
  CrossrefPubMedGoogle Scholar
• 27 Sirica A E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.  Hepatology. 2005;  41 (1) 5-15
  CrossrefPubMedGoogle Scholar
• 28 Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.  J Gastroenterol Hepatol. 2002;  17 (10) 1056-1063
  CrossrefPubMedGoogle Scholar
• 29 Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma.  J Hepatobiliary Pancreat Surg. 2003;  10 (4) 265-281
  CrossrefPubMedGoogle Scholar
• 30 Berthiaume E P, Wands J. The molecular pathogenesis of cholangiocarcinoma.  Semin Liver Dis. 2004;  24 (2) 127-137
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Sia D, Hoshida Y, Villanueva A et al.. Molecular classification of human intrahepatic cholangiocarcinoma defines two classes with distinct biology and outcome.  Hepatology. 2010;  52 374A (Abstract)
  PubMedGoogle Scholar
• 32 Khan S A, Thomas H C, Toledano M B, Cox I J, Taylor-Robinson S D. p53 Mutations in human cholangiocarcinoma: a review.  Liver Int. 2005;  25 (4) 704-716
  Google Scholar
• 33 Okabe H, Beppu T, Hayashi H et al.. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.  Ann Surg Oncol. 2009;  16 (9) 2555-2564
  CrossrefPubMedGoogle Scholar
• 34 Torbenson M, Yeh M M, Abraham S C. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis.  Am J Surg Pathol. 2007;  31 (9) 1410-1413
  CrossrefPubMedGoogle Scholar
• 35 Wu T T, Levy M, Correa A M, Rosen C B, Abraham S C. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases.  Cancer. 2009;  115 (19) 4564-4575
  CrossrefPubMedGoogle Scholar
• 36 Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M. Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States.  Hum Pathol. 2006;  37 (9) 1211-1216
  CrossrefPubMedGoogle Scholar
• 37 Gerber M A. Histopathology of HCV infection.  Clin Liver Dis. 1997;  1 (3) 529-541, vi
  CrossrefPubMedGoogle Scholar
• 38 Redston M S, Wanless I R, Redston M S, Wanless I R. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected].  Mod Pathol. 1996;  9 (3) 233-237
  PubMedGoogle Scholar
• 39 Desmet V J. Congenital diseases of intrahepatic bile ducts: variations on the theme “ductal plate malformation”.  Hepatology. 1992;  16 (4) 1069-1083
  CrossrefPubMedGoogle Scholar
• 40 Colombari R, Tsui W M. Biliary tumors of the liver.  Semin Liver Dis. 1995;  15 (4) 402-413
  Article in Thieme ConnectPubMedGoogle Scholar
• 41 Ishak K G, Goodman Z D, Stocker J T. Tumors of the liver and intrahepatic bile ducts. In: Rosai J, Sobin L H, eds. Atlas of Tumor Pathology. Washington, DC: AFIP; 1999: 245-270
  Google Scholar
• 42 Washington K. Liver neoplasms. In: Iacobuzio-Donahue C A, Montgomery E A, eds. Gastrointestinal and Liver Pathology. Philadelphia: Churchill Livingstone Elsevier; 2005: 582-632
  Google Scholar
• 43 Goodman Z D. Neoplasms of the liver.  Mod Pathol. 2007;  20 (Suppl 1) S49-S60
  CrossrefPubMedGoogle Scholar
• 44 Ferrel L D. Benign and malignant tumors of the liver. In: Odze R D, Goldblum J R, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Philadelphia: Saunders Elsevier; 2009: 1291-1325
  Google Scholar
• 45 Jain D, Sarode V R, Abdul-Karim F W, Homer R, Robert M E. Evidence for the neoplastic transformation of Von-Meyenburg complexes.  Am J Surg Pathol. 2000;  24 (8) 1131-1139
  CrossrefPubMedGoogle Scholar
• 46 Jain D, Ahrens W, Finkelstein S. Molecular evidence for the neoplastic potential of hepatic Von-Meyenburg complexes.  Appl Immunohistochem Mol Morphol. 2010;  18 (2) 166-171
  PubMedGoogle Scholar
• 47 Song J S, Lee Y J, Kim K W, Huh J, Jang S J, Yu E. Cholangiocarcinoma arising in von Meyenburg complexes: report of four cases.  Pathol Int. 2008;  58 (8) 503-512
  CrossrefPubMedGoogle Scholar
• 48 Xu A M, Xian Z H, Zhang S H, Chen X F. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature.  Eur J Gastroenterol Hepatol. 2009;  21 (5) 580-584
  CrossrefPubMedGoogle Scholar
• 49 Bhathal P S, Hughes N R, Goodman Z D. The so-called bile duct adenoma is a peribiliary gland hamartoma.  Am J Surg Pathol. 1996;  20 (7) 858-864
  CrossrefPubMedGoogle Scholar
• 50 Allaire G S, Rabin L, Ishak K G, Sesterhenn I A. Bile duct adenoma. A study of 152 cases.  Am J Surg Pathol. 1988;  12 (9) 708-715
  CrossrefPubMedGoogle Scholar
• 51 Tsui WMS, Loo K T, Chow LTC, Tse CCH. Biliary adenofibroma. A heretofore unrecognized benign biliary tumor of the liver.  Am J Surg Pathol. 1993;  17 (2) 186-192
  CrossrefPubMedGoogle Scholar
• 52 Varnholt H, Vauthey J N, Dal Cin P et al.. Biliary adenofibroma: a rare neoplasm of bile duct origin with an indolent behavior.  Am J Surg Pathol. 2003;  27 (5) 693-698
  CrossrefPubMedGoogle Scholar
• 53 Roskams T, van den Oord J J, De Vos R, Desmet V J. Neuroendocrine features of reactive bile ductules in cholestatic liver disease.  Am J Pathol. 1990;  137 (5) 1019-1025
  PubMedGoogle Scholar
• 54 Gütgemann I, Haas S, Berg J P, Zhou H, Büttner R, Fischer H P. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions.  Virchows Arch. 2006;  448 (4) 407-411
  CrossrefPubMedGoogle Scholar
• 55 Guglielmi A, Ruzzenente A, Campagnaro T et al.. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.  World J Surg. 2009;  33 (6) 1247-1254
  CrossrefPubMedGoogle Scholar
• 56 Nakanuma Y, Sasaki M, Ikeda H et al.. Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis.  Hepatol Res. 2008;  38 (4) 325-334
  CrossrefPubMedGoogle Scholar
• 57 Shiota K, Taguchi J, Nakashima O, Nakashima M, Kojiro M. Clinicopathologic study on cholangiolocellular carcinoma.  Oncol Rep. 2001;  8 (2) 263-268
  PubMedGoogle Scholar
• 58 Komuta M, Spee B, Vander Borght S et al.. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.  Hepatology. 2008;  47 (5) 1544-1556
  CrossrefPubMedGoogle Scholar
• 59 Kanamoto M, Yoshizumi T, Ikegami T et al.. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver: a case report.  J Med Invest. 2008;  55 (1-2) 161-165
  CrossrefPubMedGoogle Scholar
• 60 Steiner P E, Higginson J. Cholangiolocellular carcinoma of the liver.  Cancer. 1959;  12 (4) 753-759
  CrossrefPubMedGoogle Scholar
• 61 Theise N D, Saxena R, Portmann B C et al.. The canals of Hering and hepatic stem cells in humans.  Hepatology. 1999;  30 (6) 1425-1433
  CrossrefPubMedGoogle Scholar
• 62 Sempoux C, Fan C, Singh P et al.. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction.  Semin Liver Dis. 2011;  31 (1) 92-98
  PubMedGoogle Scholar
• 63 Kozaka K, Sasaki M, Fujii T et al.. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’.  Histopathology. 2007;  51 (3) 390-400
  CrossrefPubMedGoogle Scholar
• 64 Theise N D, Nakashima O, Park Y N, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman F T, Carneiro F, Hruban R H, Theise N D, eds. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010: 225-227
  Google Scholar
• 65 Allen R A, Lisa J R. Combined liver cell and bile duct carcinoma.  Am J Pathol. 1949;  25 (4) 647-655
  PubMedGoogle Scholar
• 66 Goodman Z D, Ishak K G, Langloss J M, Sesterhenn I A, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.  Cancer. 1985;  55 (1) 124-135
  CrossrefPubMedGoogle Scholar
• 67 Ward S C, Huang J, Tickoo S K, Thung S N, Ladanyi M, Klimstra D S. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.  Mod Pathol. 2010;  23 (9) 1180-1190
  CrossrefPubMedGoogle Scholar
• 68 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.  Gastroenterology. 2003;  125 (1) 89-97
  CrossrefPubMedGoogle Scholar
• 69 Shafizadeh N, Ferrell L D, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.  Mod Pathol. 2008;  21 (8) 1011-1018
  CrossrefPubMedGoogle Scholar
• 70 Aoki K, Takayasu K, Kawano T et al.. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings.  Hepatology. 1993;  18 (5) 1090-1095
  CrossrefPubMedGoogle Scholar
• 71 Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.  Hum Pathol. 1995;  26 (9) 956-964
  CrossrefPubMedGoogle Scholar
• 72 Cazals-Hatem D, Rebouissou S, Bioulac-Sage P et al.. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.  J Hepatol. 2004;  41 (2) 292-298
  CrossrefPubMedGoogle Scholar
• 73 Theise N D, Yao J L, Harada K et al.. Hepatic ‘stem cell’ malignancies in adults: four cases.  Histopathology. 2003;  43 (3) 263-271
  CrossrefPubMedGoogle Scholar
• 74 Ward S C, Thung S N, Lim K H et al.. Hepatic progenitor cells in liver cancers from Asian children.  Liver Int. 2010;  30 (1) 102-111
  CrossrefPubMedGoogle Scholar
• 75 Kim H, Park C, Han K H et al.. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype.  J Hepatol. 2004;  40 (2) 298-304
  CrossrefPubMedGoogle Scholar
• 76 Nakanuma Y, Sripa B, Vatanasapt V, Leong A SY, Ponchon T, Ishak K G. Intrahepatic cholangiocarcinoma. In: Hamilton S R, Aaltonen L A, eds. WHO Classification of Tumours, Pathology and Genetics. Tumours of the Digestive System. Lyon: IARC Press; 2000: 173-180
  Google Scholar
• 77 Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.  Oncogene. 2006;  25 (27) 3818-3822
  CrossrefPubMedGoogle Scholar
• 78 Lee C H, Chang C J, Lin Y J, Yeh C N, Chen M F, Hsieh S Y. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma.  Br J Cancer. 2009;  100 (11) 1765-1770
  CrossrefPubMedGoogle Scholar
• 79 Rullier A, Le Bail B, Fawaz R, Blanc J F, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.  Am J Surg Pathol. 2000;  24 (6) 870-876
  CrossrefPubMedGoogle Scholar
• 80 Mosnier J F, Kandel C, Cazals-Hatem D et al.. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.  Mod Pathol. 2009;  22 (2) 182-190
  CrossrefPubMedGoogle Scholar
• 81 Lamps L W, Folpe A L. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.  Adv Anat Pathol. 2003;  10 (1) 39-43
  CrossrefPubMedGoogle Scholar
• 82 Stroescu C, Herlea V, Dragnea A, Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.  J Gastrointestin Liver Dis. 2006;  15 (1) 9-14
  PubMedGoogle Scholar
• 83 Pan C C, Chen P C, Tsay S H, Chiang H. Cytoplasmic immunoreactivity for thyroid transcription factor-1 in hepatocellular carcinoma: a comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique.  Am J Clin Pathol. 2004;  121 (3) 343-349
  CrossrefPubMedGoogle Scholar
• 84 Lai Y S, Thung S N, Gerber M A, Chen M L, Schaffner F. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas.  Arch Pathol Lab Med. 1989;  113 (2) 134-138
  PubMedGoogle Scholar
• 85 Leong A S, Sormunen R T, Tsui W M, Liew C T. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.  Histopathology. 1998;  33 (4) 318-324
  CrossrefPubMedGoogle Scholar
• 86 Lau S K, Prakash S, Geller S A, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.  Hum Pathol. 2002;  33 (12) 1175-1181
  CrossrefPubMedGoogle Scholar
• 87 Durnez A, Verslype C, Nevens F et al.. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin.  Histopathology. 2006;  49 (2) 138-151
  CrossrefPubMedGoogle Scholar
• 88 Uenishi T, Kubo S, Yamamoto T et al.. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence.  Cancer Sci. 2003;  94 (10) 851-857
  CrossrefPubMedGoogle Scholar
• 89 Zhuang P Y, Zhang J B, Zhu X D et al.. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor.  Cancer. 2008;  112 (12) 2740-2748
  CrossrefPubMedGoogle Scholar
• 90 Edge S B. Intrahepatic bile ducts. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009: 247-254
  Google Scholar
• 91 Nathan H, Pawlik T M. Staging of intrahepatic cholangiocarcinoma.  Curr Opin Gastroenterol. 2010;  26 (3) 269-273
  CrossrefPubMedGoogle Scholar
• 92 Nathan H, Aloia T A, Vauthey J N et al.. A proposed staging system for intrahepatic cholangiocarcinoma.  Ann Surg Oncol. 2009;  16 (1) 14-22
  CrossrefPubMedGoogle Scholar
• 93 Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients.  Ann Surg Oncol. 2009;  16 (2) 404-412
  CrossrefPubMedGoogle Scholar
• 94 Nuzzo G, Giuliante F, Ardito F et al.. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection.  Updates Surg. 2010;  62 (1) 11-19
  CrossrefPubMedGoogle Scholar
• 95 Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment.  J Hepatol. 1991;  13 (3) 372-374
  CrossrefPubMedGoogle Scholar

Swan N ThungM.D. 

Department of Pathology, Box 1194, The Mount Sinai Medical Center

One Gustave L. Levy Place, New York, NY 10029

Email: swan.thung@mountsinai.org